RNAi Technologies and Global Markets

Published - Jan 2016| Analyst - Shalini Shahani Dewan| Code - BIO127B
RNAi Technologies and Global Markets
Single User License: $2,750 Member Price: FREE

Report Highlights

The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.

Report Includes

  • An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
  • Examination of significant deals in the RNAi technologies sector during the last decade
  • A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
  • Profiles of major players in the industry

Report Scope

BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.

The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).

MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.

BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Oct-2013| Analyst - Faqing Yuan| Code - BIO127A

Report Highlights

The global RNAi research tool and reagent, therapeutic, diagnostic, and agriculture market was valued at $210.2 million in 2012. The RNAi market is expected to reach $220.3 million in 2013 and $290 million by 2018, with a compound annual growth rate (CAGR) of 5.7% for the period of 2013 to 2018.

Report Includes

  • An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics.
  • Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 to 2018.
  • A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application).
  • Examination of significant deals in the RNAi technologies sector during the last decade.
  • Comprehensive company profiles of major players in the market.
RELATED REPORTS
Share This Report